Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
10E8.4/iMab in People With HIV
NCT05890963Phase 1Active, not recruiting
- Start
- Nov 2023
- Primary completion
- Apr 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of 10E8.4/iMab in human immunodeficiency virus infection (HIV) (5 arms). Primary endpoints: Number of Grade 3 or higher antibody-related reactogenicity and adverse events at Week 48, Change in plasma HIV RNA at Day 14 and 1 more. Started Nov 2023; status: active, not recruiting.
02
Drugs
10E8.4/iMab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05890963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05890963.